GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

GE HealthCare Technologies Inc.

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on GE Healthcare Technologies Inc, with a price target of $95.00....

Jefferies Sticks to Its Buy Rating for GE Healthcare Technologies Inc (GEHC)

In a report released today, Matt Miksic from Barclays maintained a Hold rating on GE Healthcare Technologies Inc, with a price target of $86.00. Mi...

Barclays Reaffirms Their Hold Rating on GE Healthcare Technologies Inc (GEHC)

Jefferies Keeps Their Buy Rating on GE Healthcare Technologies Inc (GEHC)

Barclays analyst Matt Miksic maintained a Hold rating on GE Healthcare Technologies Inc today and set a price target of $86.00. According to TipRan...

Barclays Sticks to Their Hold Rating for GE Healthcare Technologies Inc (GEHC)

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on GE Healthcare Technologies Inc, with a price target of $91.0...

Current Quarter	$1.43	Next Quarter	$1.02
Current Year	$4.57	Next Year	$4.95
QoQ Growth	-28.7%	YoY Growth	+8.3%
3Y EPS CAGR	+43.3%	Target Price	$88.05
Consensus	Buy	Upside	+4.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GEHC	$83.96	-2.43%	2.39M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GEHC	$83.96	-2.4%	2.39M
3
4
5
6

GEHC

GEHC

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get GE HealthCare Technologies Inc. Data in Excel

Get GE HealthCare Technologies Inc. Data in Excel